Zevra Therapeutics’ (ZVRA) “Overweight” Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald reissued their overweight rating on shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $25.00 price target on the stock. Cantor Fitzgerald also issued estimates for Zevra Therapeutics’ FY2025 earnings at ($0.24) EPS. ZVRA has been the topic of several […]
Cantor Fitzgerald reissued their overweight rating on shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $25.00 price target on the stock. Cantor Fitzgerald also issued estimates for Zevra Therapeutics’ FY2025 earnings at ($0.24) EPS. ZVRA has been the topic of several […]
